ABBV
3 tracked calls · 2 long · 1 short · last 90d: 2L/0S
first called by All-In Podcast 6mo ago
LONG1mo ago
“it's going to be one of the best-selling drugs … this controversy will be forgotten.”Martin Shkreli Streams
AbbVie a long, Vyalev becomes one of best selling drugs once controversy fades
ABBVLONG@ $257.99
$255.27-1.05%
since call Jun 26
peak +5.4%
LONG1mo ago
“I'm bullish on AbbVie. … Biotech is a game that unfolds over years, not over days”Martin Shkreli Streams
AbbVie bullish, a multi-year biotech story to be patient with
ABBVLONG@ $241.29
$255.27+5.80%
since call Jun 25
peak +9.8%
SHORT6mo ago
“We have changed the requirements so that we use the same principles we use for small molecules... we are shortening the timeframe from 5 to 8 years to 2.5…”All-In Podcast
FDA slashes biosimilar approval from 5-8yrs to 2.5yrs, opening floodgates that erode branded biologic pricing
ABBVSHORT@ $218.21
$255.27-16.99%
since call Jan 15